Immediate Impact

7 from Science/Nature 59 standout
Sub-graph 1 of 24

Citing Papers

Engineered commensals for targeted nose-to-brain drug delivery
2025 Standout
Targeted protein degradation: advances in drug discovery and clinical practice
2024 Standout
1 intermediate paper

Works of Ann Polonskaia being referenced

Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN
2019
Iberdomide (CC-220) Has Synergistic Anti-Tumor and Immunostimulatory Activity Against Multiple Myeloma in Combination with Both Bortezomib and Dexamethasone, or in Combination with Daratumumab in Vitro
2018
and 1 more

Author Peers

Author Last Decade Papers Cites
Ann Polonskaia 320 135 113 10 433
Lukas Orel 249 30 64 15 425
Luisa Caione 180 61 66 8 438
Kate F. Whitecross 289 34 93 6 373
Hans L. P. van Duijnhoven 269 38 99 10 504
Terry A. Woodford 351 19 62 8 451
Judith L. Scott 127 58 47 9 386
Hélène Favre 205 49 241 10 498
T W Dolby 258 73 57 10 476
Kerrie Wilson 145 140 118 10 468
Satoshi Yoshimura 178 29 73 13 376

All Works

Loading papers...

Rankless by CCL
2026